inclusion criteria: 1. willing and able to provide informed consent. 2. male or female patients between 18 and 80 years of age. 3. oxygen saturation \<94% in room air at screening. 4. hospitalized with mild covid 19 disease (not requiring oxygen therapy \[who covid-19 clinical improvement ordinal scale, score of 3\] or requiring oxygen therapy by mask or nasal prong \[who covid-19 clinical improvement ordinal scale, score of 4\]). requirement of oxygen therapy by mask with reservoir to treat severe covid 19 pneumonia is not allowed for enrollment. note: hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat covid-19 patients. 5. chest x ray or computerized tomography (ct) scan consistent with pneumonia. 6. onset of covid-19 symptoms within 2 weeks prior to randomization. 7. severe acute respiratory syndrome coronavirus 2 (sars cov 2) infection confirmed by a polymerase chain reaction (pcr) test, antigen, or any authorized commercial or public health assay (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing). 8. male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception. 9. female patients of childbearing potential must have a negative pregnancy test at screening or pretreatment on day 1. 10. male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from day 1 until 90 days after the last dose of study treatment. 11. patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.

inclusion criteria: 1. willing and able to provide informed consent. 2. male or female patients between 18 and 80 years of age. 3. oxygen saturation \<94% in room air at screening. 4. hospitalized with mild covid 19 disease (not requiring oxygen therapy \[who covid-19 clinical improvement ordinal scale, score of 3\] or requiring oxygen therapy by mask or nasal prong \[who covid-19 clinical improvement ordinal scale, score of 4\]). requirement of oxygen therapy by mask with reservoir to treat severe covid 19 pneumonia is not allowed for enrollment. note: hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat covid-19 patients. 5. chest x ray or computerized tomography (ct) scan consistent with pneumonia. 6. onset of covid-19 symptoms within 2 weeks prior to randomization. 7. severe acute respiratory syndrome coronavirus 2 (sars cov 2) infection confirmed by a polymerase chain reaction (pcr) test, antigen, or any authorized commercial or public health assay (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing). 8. male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception. 9. female patients of childbearing potential must have a negative pregnancy test at screening or pretreatment on day 1. 10. male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from day 1 until 90 days after the last dose of study treatment. 11. patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.

inclusion criteria: willing and able to provide informed consent. male or female patients between 18 and 80 years of age. oxygen saturation <94% in room air at screening. hospitalized with mild covid 19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3] or requiring oxygen therapy by mask or nasal prong [who covid-19 clinical improvement ordinal scale, score of 4]). requirement of oxygen therapy by mask with reservoir to treat severe covid 19 pneumonia is not allowed for enrollment. note: hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat covid-19 patients. chest x ray or computerized tomography (ct) scan consistent with pneumonia. onset of covid-19 symptoms within 2 weeks prior to randomization. severe acute respiratory syndrome coronavirus 2 (sars cov 2) infection confirmed by a polymerase chain reaction (pcr) test, antigen, or any authorized commercial or public health assay (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing). male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception. female patients of childbearing potential must have a negative pregnancy test at screening or pretreatment on day 1. male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from day 1 until 90 days after the last dose of study treatment. patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.

inclusion criteria: willing and able to provide informed consent. male or female patients between 18 and 80 years of age. oxygen saturation <94% in room air at screening. hospitalized with mild covid 19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3] or requiring oxygen therapy by mask or nasal prong [who covid-19 clinical improvement ordinal scale, score of 4]). requirement of oxygen therapy by mask with reservoir to treat severe covid 19 pneumonia is not allowed for enrollment. note: hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat covid-19 patients. chest x ray or computerized tomography (ct) scan consistent with pneumonia. onset of covid-19 symptoms within 2 weeks prior to randomization. severe acute respiratory syndrome coronavirus 2 (sars cov 2) infection confirmed by a polymerase chain reaction (pcr) test, antigen, or any authorized commercial or public health assay (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing). male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception. female patients of childbearing potential must have a negative pregnancy test at screening or pretreatment on day 1. male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from day 1 until 90 days after the last dose of study treatment. patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.

inclusion criteria: 1. willing and able to provide informed consent. 2. male or female patients between 18 and 80 years of age. 3. oxygen saturation <94% in room air at screening. 4. hospitalized with mild covid 19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3] or requiring oxygen therapy by mask or nasal prong [who covid-19 clinical improvement ordinal scale, score of 4]). requirement of oxygen therapy by mask with reservoir to treat severe covid 19 pneumonia is not allowed for enrollment. note: hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat covid-19 patients. 5. chest x ray or computerized tomography (ct) scan consistent with pneumonia. 6. onset of covid-19 symptoms within 2 weeks prior to randomization. 7. severe acute respiratory syndrome coronavirus 2 (sars cov 2) infection confirmed by a polymerase chain reaction (pcr) test, antigen, or any authorized commercial or public health assay (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing). 8. male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception. 9. female patients of childbearing potential must have a negative pregnancy test at screening or pretreatment on day 1. 10. male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from day 1 until 90 days after the last dose of study treatment. 11. patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.

inclusion criteria: 1. willing and able to provide informed consent. 2. male or female patients between 18 and 80 years of age. 3. oxygen saturation <94% in room air at screening. 4. hospitalized with mild covid 19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3] or requiring oxygen therapy by mask or nasal prong [who covid-19 clinical improvement ordinal scale, score of 4]). requirement of oxygen therapy by mask with reservoir to treat severe covid 19 pneumonia is not allowed for enrollment. note: hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat covid-19 patients. 5. chest x ray or computerized tomography (ct) scan consistent with pneumonia. 6. onset of covid-19 symptoms within 2 weeks prior to randomization. 7. severe acute respiratory syndrome coronavirus 2 (sars cov 2) infection confirmed by a polymerase chain reaction (pcr) test, antigen, or any authorized commercial or public health assay (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing). 8. male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception. 9. female patients of childbearing potential must have a negative pregnancy test at screening or pretreatment on day 1. 10. male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from day 1 until 90 days after the last dose of study treatment. 11. patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.

inclusion criteria: 1. willing and able to provide informed consent. 2. male or female patients between 18 and 80 years of age. 3. hospitalized with covid 19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3] or requiring oxygen therapy by mask or nasal prong [who covid-19 clinical improvement ordinal scale, score of 4]). note: hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat covid-19 patients. 4. chest x ray or computerized tomography (ct) scan consistent with mild to moderate pneumonia. 5. onset of covid-19 symptoms within 5 days prior to screening. 6. sars cov 2 infection confirmed by a polymerase chain reaction (pcr) test (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing). 7. male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception. 8. females patients of childbearing potential must have a negative pregnancy test at screening or pretreatment on day 1. 9. male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from day 1 until 90 days after the last dose of study treatment. 10. patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.

inclusion criteria: 1. willing and able to provide informed consent. 2. male or female patients between 18 and 80 years of age. 3. hospitalized with covid 19 disease (not requiring oxygen therapy [who covid-19 clinical improvement ordinal scale, score of 3] or requiring oxygen therapy by mask or nasal prong [who covid-19 clinical improvement ordinal scale, score of 4]). note: hospitalized patients can also include patients admitted to centers conditioned as hospitals to treat covid-19 patients. 4. chest x ray or computerized tomography (ct) scan consistent with mild to moderate pneumonia. 5. onset of covid-19 symptoms within 5 days prior to screening. 6. sars cov 2 infection confirmed by a polymerase chain reaction (pcr) test (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing). 7. male patients and female patients of childbearing potential must agree to use protocol-specified methods of contraception. 8. females patients of childbearing potential must have a negative pregnancy test at screening or pretreatment on day 1. 9. male patients must agree not to donate sperm from the first dose through 90 days after the last dose of study treatment; female patients of childbearing potential should refrain from donation of ova from day 1 until 90 days after the last dose of study treatment. 10. patient is, in the opinion of the investigator, willing and able to comply with the study treatment regimen and all other study requirements.